-At present, 19 start-ups are driving innovation in this domain; various R&D initiatives have been undertaken by these players over the last few years
Intranasal Therapeutics Market Overview
The nasal drug delivery market is estimated to be worth $2.9 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 18% during the forecast period. Over the past few years, the prevalence of neurological disorders has increased at an annualized rate of 10.9%. Further, the mortality associated with such diseases is projected to account for 12.2% of the global death rate, in 2030. In this context, several research initiatives are underway to identify an approach that allows effective delivery of the target medication directly into the brain. One key challenge currently faced by researchers is the presence of the complex blood brain barrier (BBB), which hinders the entry of the target drug into the CNS, acting as a significant roadblock in the development of effective treatment modalities. It is worth mentioning that the failure of the ongoing research initiatives can incur losses worth USD 2 billion. As a result, stakeholders in the pharmaceutical domain have shifted their focus towards the use of intranasal treatments, which have demonstrated to be capable of bypassing the blood brain barrier, thereby, delivering the target drug directly into the brain. Clinical studies related to interventional intranasal therapies have increased three-folds over the last decade. Specifically, post the onset of the COVID-19 pandemic, extensive research focused on intranasal therapeutics is being carried out due to their proven pharmacological value and favorable safety profiles. Notable examples of intranasal COVID-19 targeting drugs that are currently being evaluated across different phases of development include (in alphabetical order) COVIDROPS™ (Sorrento Therapeutics), DEXANEUROSONE™ (Biomed Industries™) and Zavegepant (Biohaven Pharmaceuticals) .
Despite the several advantages offered by the intranasal route of administration, the delivery of therapies via the aforementioned approach is associated with some challenges, such as mucus and epithelial barriers, low bioavailability of drugs, limited drug absorption and shorter residence time. Most of these concerns can be mitigated via the use of appropriate drug delivery systems. Therefore, several pharmaceutical companies are currently focused on the development of novel drug delivery systems for intranasal therapeutics, since conventional pharmaceutical dosage forms are unable to regulate the rate at which these drugs are delivered to the target site. At present, close to 40 intranasal drug delivery systems are available in the market. Additionally, USD 5.5 billion was invested in this domain, during 2016-2021. In the same time frame, multiple partnership agreements were established between various stakeholders. Driven by the increasing patient population and the growing demand for such therapeutics, this market is anticipated to witness steady growth in the coming years.
Key Companies Developing Intranasal Drugs and Nasal Drug Delivery System in Nasal Drug Delivery Market
Examples of key companies engaged in nasal drug delivery market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Aptar Pharma, Nemera, Teleflex, Mystic Pharmaceuticals and Zeteo Medical. This nasal drug delivery market report includes an easily searchable excel database of all the companies developing intranasal drugs and nasal drug delivery system, worldwide.
Recent Developments in Intranasal Therapeutics Market:
Several recent developments have taken place in the field of intranasal therapeutics. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
- In August 2023, Tiziana Life Sciences announced the FDA clearance of intranasal Foralumab for the treatment of patients suffering from alzheimer’s disease.
- In June 2023, the FDA announced the extension of its eview period of the New Drug Application (NDA) for neffy® (intranasal (IN) epinephrine) for the treatment of severe allergic reactions.
- In June 2023, Seelos Therapeutics announced the closure of enrollment of its registration directed study focusing on SLS-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior in adults suffering from major depressive disorder.
Scope of the Report
The “Intranasal Therapeutics and Drug Delivery Systems Market Distribution by Target Indication (Acute Repetitive Clusters, Anaphylaxis, COVID-19, Dry Eye Disease, Hypoglycemia, Influenza, Major Depressive Disorder, Migraine, Nasal Polyps and Prader-Willi Syndrome), Type of Molecule (Biologics and Small Molecule) and Geography (North America, Europe, Asia-Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and the likely future potential associated with the intranasal therapeutics and drug delivery systems market. The study also includes an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.
Amongst other elements, the report features:
- A detailed overview of the overall market landscape of players engaged in providing intranasal drug delivery systems, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, type of dosage form (liquid, powder and spray) and type of system (unit dose, multi dose and metered dose).
- A detailed overview of the overall market landscape of players engaged in providing intranasal therapeutics, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, phase of development (phase I, phase II, Phase II/III, Phase III and Approved), type of molecule (biologics and small molecule) and therapeutic area (cardiovascular disorders, ear disorders, genetic disorders, infectious disorders, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders, ophthalmic disorders, respiratory disorders and other disorders)
- An in-depth company competitiveness analysis of intranasal drug delivery system providers based on company strength (in terms of experience and company size), and product portfolio strength (such as number of products, type of dosage form, type of system and volume range).
- An in-depth analysis of completed, ongoing and planned clinical trials focused on intranasal therapeutics, based on several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, study design, leading industry sponsors / collaborators (in terms of number of trials conducted), trial focus, target indication, most popular indications and key geographical regions.
- An analysis of the recent partnerships inked between various players engaged in the development of intranasal therapeutics, during the period 2016-2021. Additionally, it includes a brief description of the various types of partnership models (such as service agreements, licensing agreements (specific to affiliated technology platforms and product candidates), technology utilization agreements, product manufacturing agreements, product development and commercialization agreements, clinical trial agreements) that have been adopted by stakeholders engaged in this domain.
- A detailed analysis of various investments, such as venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings that were undertaken by players engaged in this domain, during the period 2016-2021.
- An analysis of the start-ups (established between 2011-2020; less than 200 employees) engaged in this domain, based on several parameters, such as number of candidates in discovery, preclinical and clinical phases of development, number of partnerships, number of patents, amount raised, number of investors, types of funding and number of deals inked.
- An in-depth analysis of patents related to intranasal therapeutics and drug delivery systems, filed / granted, based on various parameters, such as patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, type of applicant, and leading players (in terms of number of patents). In addition, it features a patent valuation analysis, highlighting the qualitative and quantitative aspects of patents.
- A detailed discussion on the various steps of the supply chain model, namely concept of development & proof of concept, research and development, regulatory approvals and marketing and sales of the intranasal drug delivery systems and the cost requirements across each of the aforementioned stages.
One of the key objectives of the report was to evaluate the current opportunity and future growth potential within the intranasal therapeutics and drug delivery systems market, over the next decade. We have also provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, over the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] target indication (acute repetitive clusters, anaphylaxis, COVID-19, dry eye disease, hypoglycemia, influenza, major depressive disorder, migraine, nasal polyps and prader-willi syndrome), [B] type of molecule (biologics and small molecules) and [C] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World). In order to account for future uncertainties and add robustness to our forecast model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Frequently Asked Questions
Question 1: What are intranasal therapeutics? Answer:
Intranasal therapeutics encompass a wide array of pharmaceuticals which are administered via the intranasal route for better and quick absorption of the drug.
Question 2: How big is the nasal drug delivery market? Answer:
The nasal drug delivery market size is estimated to be worth $2.9 billion in 2022.
Question 3: What is the projected market growth of the nasal drug delivery market? Answer:
The nasal drug delivery market is expected to grow at compounded annual growth rate (CAGR) of 18% during the forecast period 2022 - 2035.
Question 4: Who are the leading companies in the nasal drug delivery market? Answer:
Examples of key companies engaged in nasal drug delivery market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Aptar Pharma, Nemera, Teleflex, Mystic Pharmaceuticals and Zeteo Medical.
Question 5: How many drug candidates are currently being evaluated by companies engaged in the nasal drug delivery market? Answer:
Over 65 drug candidates are currently being evaluated by players engaged in the nasal drug delivery market.
Question 6: How many drug delivery systems are currently marketed / under development by companies engaged in the nasal drug delivery market? Answer:
More than 40 drug delivery systems are currently marketed / under development by companies engaged in the nasal drug delivery market.
Question 7: Which region is the hub for companies engaged in the nasal drug delivery market? Answer:
North America emerged as the hub for companies engaged in the nasal drug delivery market, with over 75% of the players established in the region.